|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM108242811 |
| 003 |
DE-627 |
| 005 |
20231222144743.0 |
| 007 |
tu |
| 008 |
231222s2000 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0361.xml
|
| 035 |
|
|
|a (DE-627)NLM108242811
|
| 035 |
|
|
|a (NLM)10900161
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Foster, M P
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Humoral and cell-mediated immunity in mice with genetic deficiencies of prolactin, growth hormone, insulin-like growth factor-I, and thyroid hormone
|
| 264 |
|
1 |
|c 2000
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 21.09.2000
|
| 500 |
|
|
|a Date Revised 21.11.2008
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright 2000 Academic Press.
|
| 520 |
|
|
|a Prolactin (PRL), growth hormone (GH), insulin-like growth factor-I (IGF-I), and thyroid hormones have been proposed as critical immunoregulatory mediators, and their clinical use is being considered. The precise role played by each of these hormones in the generation of humoral and cell-mediated immune responses was assessed in a panel of mice with mutations that result in a selective reduction of PRL, GH, IGF-I, and/or thyroid hormone production. A surprising result, in view of previous studies indicating an immunoregulatory role for these hormones, was that all mice generated normal humoral and cell-mediated immune responses following challenge with T-independent and T-dependent antigens and with Listeria monocytogenes. A review of these findings in the context of previous data has resulted in the formulation of a working hypothesis proposing that these hormones act as anabolic and/or stress modulating mediators with effects on most cells, including those of the immune system. When considered in this context, it is possible to reconcile the contradictory data
|
| 650 |
|
4 |
|a Comparative Study
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Research Support, U.S. Gov't, P.H.S.
|
| 650 |
|
7 |
|a Hormones
|2 NLM
|
| 650 |
|
7 |
|a Thyroid Hormones
|2 NLM
|
| 650 |
|
7 |
|a Insulin-Like Growth Factor I
|2 NLM
|
| 650 |
|
7 |
|a 67763-96-6
|2 NLM
|
| 650 |
|
7 |
|a Prolactin
|2 NLM
|
| 650 |
|
7 |
|a 9002-62-4
|2 NLM
|
| 650 |
|
7 |
|a Growth Hormone
|2 NLM
|
| 650 |
|
7 |
|a 9002-72-6
|2 NLM
|
| 700 |
1 |
|
|a Jensen, E R
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Montecino-Rodriguez, E
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Leathers, H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Horseman, N
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dorshkind, K
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 96(2000), 2 vom: 01. Aug., Seite 140-9
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:96
|g year:2000
|g number:2
|g day:01
|g month:08
|g pages:140-9
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 96
|j 2000
|e 2
|b 01
|c 08
|h 140-9
|